BridgeMD
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments
EU CTIS ID: 2023-509167-24-00
What this study is testing
To assess the proportion of patients who are alive without disease progression at 6 months based on local investigator assessment per RECIST v1.1 separately in cohorts A and C (alpelisib in combination with fulvestrant) and cohort B (alpelisib in combination with letrozole) among patients with HR+, HER2-negative aBC harboring a PIK3CA mutation who have progressed on or after prior treatments
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient is an adult male or female ≥ 18 years old
- Patient has adequate bone marrow function
- Patient has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory. It is recommended to provide a tumor sample collected after the most recent progression or recurrence
- Advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy
- Patient has been confirmed as PIK3CA mutant as determined by a certified designated laboratory
- Patient has histologically and/or cytologically confirmed ER+ and/ or PgR+ BC
You likely can't join if
- Patient has received prior treatment with any PI3K inhibitors
- Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II (based on FG and HbA1c in inclusion criterion 11)
- Patient has a concurrent malignancy or malignancy within 3 years of study screening period, with the exception of adequately treated basal or squamous cell carcinoma, nonmelanoma skin cancer or curatively resected cervical cancer
- Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia)
- Patients receiving systemic corticosteroids ≤ 2 weeks prior to treatment with alpelisib
- History of acute pancreatitis within 1 year of screening or past medical history of pancreatitis
See the full eligibility criteria
- Patient is an adult male or female ≥ 18 years old
- Patient has adequate bone marrow function
- Patient has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory. It is recommended to provide a tumor sample collected after the most recent progression or recurrence
- Advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy
- Patient has been confirmed as PIK3CA mutant as determined by a certified designated laboratory
- Patient has histologically and/or cytologically confirmed ER+ and/ or PgR+ BC
- Patient has confirmed, HER2-negative aBC. HER2-negative defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+
- Patients must be diagnosed with aBC, with documented evidence of tumor progression on or after prior treatments. No more than one prior regimen of chemotherapy for the treatment of metastatic disease is permitted. The maximum number of prior therapies for aBC or mBC is limited to two (maintenance therapies, where applicable, must be regarded as part of the main therapy). Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to study entry
- Patient has either measurable disease, i.e. at least one measurable lesion as per RECIST v1.1 criteria or if no measurable disease is present than at least one predominantly lytic bone lesion must be present
- Patient has ECOG performance status of ≤ 2
- Patient has received prior treatment with any PI3K inhibitors
- Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II (based on FG and HbA1c in inclusion criterion 11)
- Patient has a concurrent malignancy or malignancy within 3 years of study screening period, with the exception of adequately treated basal or squamous cell carcinoma, nonmelanoma skin cancer or curatively resected cervical cancer
- Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia)
- Patients receiving systemic corticosteroids ≤ 2 weeks prior to treatment with alpelisib
- History of acute pancreatitis within 1 year of screening or past medical history of pancreatitis
- Patient has impaired GI function or GI disease that may affect the absorption of study drugs
- Patient has documented pneumonitis
- Patients being concurrently treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme Cytochrome P (CYP)3A within the last 5 days prior to study entry
The study team makes the final eligibility decision.
Where it's taking place
- Chile
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chile. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.